Tuberculosis, or TB, is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB). Microscopic droplets suspended in the air pass the TB organism from person to person. Infection can occur when an uninfected person comes in contact with someone who has active tuberculosis.
Two methods exist to aid in detection of latent TB – an intradermal injection known as the tuberculin skin test (TST) or blood-based tests referred to as interferon-gamma release assays (IGRAs) – with other clinical findings and risk assessment.
For in vitro diagnostic use. Refer to the instructions for use for more information.
The T-SPOT®.TB test from Revvity is an IGRA designed to enable accurate results across patient populations, even in patients with a weakened immune status1. This unique, single visit, single tube blood test reduces assay variability and maximizes sensitivity by separating T cells from whole blood and standardizing the number of these cells in each test well. The T-Cell Select™ reagent kit enables the automation of cell isolation and removes potentially interfering substances that can affect test results.1 This test design mitigates the risk of false or invalid results.
In the United States, the T-SPOT.TB test is commercially supported by EUROIMMUN US. For more information, please contact us or visit tspot.com.
| wdt_ID | Method | Parameter | Substrate | Species/ Antigen |
|---|---|---|---|---|
| 600 | ELISPOT | Antibodies against MTB antigens | Antigen coated microplate wells | |
| 601 | Cell Isolation | Peripheral blood mononuclear cells (PBMCs) | Reagent kit |
1. Oxford Immunotec. T-SPOT.TB Package Insert TB-PI-US-0001 V13. Abingdon, UK. November 2023.
2024 EUROIMMUN US
